These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27354762)

  • 41. Human leukaemic (HMC-1) and normal skin mast cells express beta 2-integrins: characterization of beta 2-integrins and ICAM-1 on HMC-1 cells.
    Weber S; Babina M; Feller G; Henz BM
    Scand J Immunol; 1997 May; 45(5):471-81. PubMed ID: 9160089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Costimulation with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 augments activation-induced death of antigen-specific CD4+ T lymphocytes.
    Damle NK; Klussman K; Leytze G; Aruffo A; Linsley PS; Ledbetter JA
    J Immunol; 1993 Sep; 151(5):2368-79. PubMed ID: 7689606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A distinct cytokines profile in tear film of dry eye disease (DED) patients with HIV infection.
    Agrawal R; Balne PK; Veerappan A; Au VB; Lee B; Loo E; Ghosh A; Tong L; Teoh SC; Connolly J; Tan P
    Cytokine; 2016 Dec; 88():77-84. PubMed ID: 27585367
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of LFA-1, ICAM-1, VLA-4 and VCAM-1 in lymphocyte migration across retinal pigment epithelial monolayers in vitro.
    Devine L; Lightman SL; Greenwood J
    Immunology; 1996 Jul; 88(3):456-62. PubMed ID: 8774365
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activation of cord T lymphocytes. III. Role of LFA-1/ICAM-1 and CD2/LFA-3 adhesion molecules in CD3-induced proliferative response.
    Gerli R; Agea E; Muscat C; Tognellini R; Fiorucci G; Spinozzi F; Cernetti C; Bertotto A
    Cell Immunol; 1993 Apr; 148(1):32-47. PubMed ID: 7684326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Co-stimulation of T cells results in distinct IL-10 and TNF-alpha cytokine profiles dependent on binding to ICAM-1, ICAM-2 or ICAM-3.
    Bleijs DA; de Waal-Malefyt R; Figdor CG; van Kooyk Y
    Eur J Immunol; 1999 Jul; 29(7):2248-58. PubMed ID: 10427988
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
    Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
    Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Binding of human rhinovirus and T cells to intercellular adhesion molecule-1 on human fibroblasts. Discordance between effects of IL-1 and IFN-gamma.
    Piela-Smith TH; Aneiro L; Korn JH
    J Immunol; 1991 Sep; 147(6):1831-6. PubMed ID: 1679837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lymphocyte migration into the CNS modelled in vitro: roles of LFA-1, ICAM-1 and VLA-4.
    Male D; Rahman J; Pryce G; Tamatani T; Miyasaka M
    Immunology; 1994 Mar; 81(3):366-72. PubMed ID: 7911447
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interleukin-18/interferon-gamma-inducing factor, a novel cytokine, up-regulates ICAM-1 (CD54) expression in KG-1 cells.
    Kohka H; Yoshino T; Iwagaki H; Sakuma I; Tanimoto T; Matsuo Y; Kurimoto M; Orita K; Akagi T; Tanaka N
    J Leukoc Biol; 1998 Oct; 64(4):519-27. PubMed ID: 9766633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial.
    Nichols KK; Holland E; Toyos MM; Peace JH; Majmudar P; Raychaudhuri A; Hamdani M; Roy M; Shojaei A
    Clin Ophthalmol; 2018; 12():263-270. PubMed ID: 29440868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: A systematic literature review.
    Holland EJ; Darvish M; Nichols KK; Jones L; Karpecki PM
    Ocul Surf; 2019 Jul; 17(3):412-423. PubMed ID: 30844466
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A monoclonal antibody directed against the human intercellular adhesion molecule (ICAM-1) modulates the release of tumor necrosis factor-alpha, interferon-gamma and interleukin 1.
    Geissler D; Gaggl S; Möst J; Greil R; Herold M; Dietrich M
    Eur J Immunol; 1990 Dec; 20(12):2591-6. PubMed ID: 1980110
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease.
    White DE; Hendrix LH; Sun L; Tam I; Macsai M; Gibson AA
    J Manag Care Spec Pharm; 2023 Jan; 29(1):69-79. PubMed ID: 36030415
    [No Abstract]   [Full Text] [Related]  

  • 55. Migration of skin-homing T cells across cytokine-activated human endothelial cell layers involves interaction of the cutaneous lymphocyte-associated antigen (CLA), the very late antigen-4 (VLA-4), and the lymphocyte function-associated antigen-1 (LFA-1).
    Santamaria Babi LF; Moser R; Perez Soler MT; Picker LJ; Blaser K; Hauser C
    J Immunol; 1995 Feb; 154(4):1543-50. PubMed ID: 7836740
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elevated expression in situ of selectin and immunoglobulin superfamily type adhesion molecules in retroocular connective tissues from patients with Graves' ophthalmopathy.
    Heufelder AE; Bahn RS
    Clin Exp Immunol; 1993 Mar; 91(3):381-9. PubMed ID: 7680294
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional epitope analysis of the human CD11a/CD18 molecule (LFA-1, lymphocyte function-associated antigen 1) involved in HIV-1-induced syncytium formation.
    Vermot-Desroches C; Rigal D; Escaich S; Bernaud J; Pichoud C; Lamelin JP; Trepo C
    Scand J Immunol; 1991 Oct; 34(4):461-70. PubMed ID: 1718027
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast.
    Guimaraes de Souza R; Yu Z; Stern ME; Pflugfelder SC; de Paiva CS
    J Ocul Pharmacol Ther; 2018 Sep; 34(7):543-549. PubMed ID: 29958030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults.
    Semba CP; Swearingen D; Smith VL; Newman MS; O'Neill CA; Burnier JP; Haughey DB; Gadek TR
    J Ocul Pharmacol Ther; 2011 Feb; 27(1):99-104. PubMed ID: 20334535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of LFA-1 and VLA-4 in the adhesion of cloned normal and LFA-1 (CD11/CD18)-deficient T cells to cultured endothelial cells. Indication for a new adhesion pathway.
    Vennegoor CJ; van de Wiel-van Kemenade E; Huijbens RJ; Sanchez-Madrid F; Melief CJ; Figdor CG
    J Immunol; 1992 Feb; 148(4):1093-101. PubMed ID: 1371131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.